Melina Higgins Net Worth

The estimated Net Worth of Melina E Higgins is at least $2.63 Milhão dollars as of 3 March 2024. Ms. Higgins owns over 18,855 units of Mylan NV stock worth over $1,620,441 and over the last 11 years she sold MYL stock worth over $610,291. In addition, she makes $398,756 as Non-Executive Independent Director at Mylan NV.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Higgins MYL stock SEC Form 4 insiders trading

Melina has made over 15 trades of the Mylan NV stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 18,855 units of MYL stock worth $298,852 on 3 March 2024.

The largest trade she's ever made was buying 35,000 units of Mylan NV stock on 28 April 2016 worth over $1,502,200. On average, Melina trades about 2,569 units every 49 days since 2013. As of 3 March 2024 she still owns at least 102,236 units of Mylan NV stock.

You can see the complete history of Ms. Higgins stock trades at the bottom of the page.

Melina Higgins biography

Melina E. Higgins serves as Non-Executive Independent Director of the Company. Ms. Higgins has been a member of the board of directors of Genworth Financial Inc. (NYSE: GNW), an insurance company, since September 2013, and serves on its Management Development & Compensation and Nominating & Corporate Governance Committees. In January 2016, Ms. Higgins became non-executive chairman of the board of directors of Antares Midco Inc., a private company that provides financing solutions for middle market, private equity-backed transactions. Ms. Higgins previously held senior roles of increasing responsibility at The Goldman Sachs Group, Inc. (NYSE: GS), a global investment banking, securities and investment management firm, including partner and managing director, during her nearly 20-year career at the firm from 1989 to 1992 and 1994 to 2010. During her tenure there, Ms. Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the largest alternative asset managers in the world. She also served as head of the Americas for Private Debt and as co-chairperson of the Investment Advisory Committee for GS Mezzanine Partners funds, which managed over $30 billion of assets and were global leaders in their industry. Ms. Higgins also is a member of the Women’s Leadership Board of Harvard University’s John F. Kennedy School of Government. As previously disclosed, Ms. Higgins will serve as a director of Viatris upon the closing of the Combination. Ms. Higgins’ qualifications to serve on Mylan’s Board include, among others, her experience and expertise in finance, capital markets, international business and strategy, international business transactions, corporate governance, and risk oversight and compliance.

What is the salary of Melina Higgins?

As the Non-Executive Independent Director of Mylan NV, the total compensation of Melina Higgins at Mylan NV is $398,756. There are 6 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of $18,509,300.

How old is Melina Higgins?

Melina Higgins is 52, she's been the Non-Executive Independent Director of Mylan NV since 2016. There are 11 older and 1 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.

What's Melina Higgins's mailing address?

Melina's mailing address filed with the SEC is C/O GENWORTH FINANCIAL, INC., 11011 WEST BROAD STREET, GLEN ALLEN, VA, 23060.

Insiders trading at Mylan NV

Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher, eRobert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.

What does Mylan NV do?

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Complete history of Ms. Higgins stock trades at Mylan NV, Genworth Inc, eViatris

Mylan NV executives and stock owners

Mylan NV executives and other stock owners filed with the SEC include:

• Heather Bresch,
  Chief Executive Officer, Executive Director
• Rajiv Malik,
  President, Executive Director
• Robert Coury,
  Executive Chairman of the Board
• Mark Parrish,
  Lead Independent Non-Executive Vice Chairman of the Board
• JoEllen Dillon,
  Non-Executive Independent Director
• Neil Dimick,
  Non-Executive Independent Director
• Melina Higgins,
  Non-Executive Independent Director
• Sjoerd Vollebregt,
  Non-Executive Independent Director
• Robert Cindrich,
  Non-Executive Independent Director
• Harry Korman,
  Non-Executive Independent Director
• Randall Vanderveen,
  Non-Executive Independent Director
• Pauline van der Meer Mohr,
  Non-Executive Independent Director
• Richard Mark,
  Non-Executive Independent Director
• Melissa Trombetta,
  Head of Global Investor Relations
• Joseph C Md Maroon,
  Director
• Rodney L Piatt,
  Director
• Paul Campbell,
  See Remarks
• Laboratories Abbott Product...,
  
• Kenneth Scott Parks,
  Chief Financial Officer
• Wendy Cameron,
  Director
• Douglas J Leech,
  Director
• Daniel Martin Jr Gallagher,
  Chief Legal Officer
• Anthony Mauro,
  Chief Commercial Officer
• John D Sheehan,
  EVP and CFO
• Laboratories Abbott Establi...,
  
• Laboratories Laboratoires F...,